However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...

However, Eli Lilly continued to develop GLP-1 drugs, getting Trulicity, which is used to treat type 2 diabetes, approved in 2014. By 2018, Trulicity would become Eli Lilly's top-selling drug ...

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...

Mounjaro sales more than doubled to $3.11 billion from $1.41 billion a year ago. The U.S. pharma giant reported third-quarter ...

Among other drugs, Jardiance, Taltz, and Humalog, should continue to see double-digit gains, while Trulicity will see a sharp decline, amid increased competition. We think Eli Lilly may see higher ...

Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to $1.30 billion. Guidance: Eli Lilly forecasts fiscal year 2024 sales of $45.4 billion—$46 billion, compared to prior guidance of ...